Trailing-twelve-month (TTM) revenue is $5.82 Billion with a year-over-year growth of +26.93%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,365,980,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-28 |
| Q4 FY2025Period ended 2025-12-31 | $1,506,835,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-10 |
| Q1 FY2026Period ended 2026-03-31 | $1,272,676,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $1,674,039,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-28 |
| TTM revenue | $5,819,530,000 |
Current P/S: $25,400,054,551 market capitalization ÷ $5,819,530,000 TTM revenue = 4.36x.
Market capitalization source: FMP quote. Quote observed 2026-09-18T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.67B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-19T00:15:43.163Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| I C L U S I G | $90M | $105M | $5M | $106M | $114M | $134M |
| J A K A F I | $1.9B | $2.2B | $338M | $2.7B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $90M | $105M | $124M | $147M | $260M | $324M |
| U [S] | N/A | $2.6B | $2.9B | N/A |
$5.82B
$5.82 Billion
+26.93%
vs. $4.58B a year ago (TTM)
+16.43%
5 Year compound annual growth rate
1 Year
+26.93%
3 Year
+18.32%
5 Year
+16.43%
10 Year
+19.99%
15 Year
+27.53%
20 Year
+34.47%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.14B | +$900.02M | +21.22% |
| 2024 | $4.24B | +$545.57M | +14.76% |
| 2023 | $3.70B | +$301.01M | +8.87% |
| 2022 | $3.39B | +$408.37M | +13.67% |
| 2021 | $2.99B | +$319.56M | +11.98% |
| 2020 |
TTM Growth
+26.93%
3-Year CAGR
+18.32%
5-Year CAGR
+16.43%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-19T00:15:43.163Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $3.2B |
| $3.6B |
| M I N J U V I | N/A | N/A | $69M | $20M | $119M | $145M |
|---|
| Milestone And Contract Revenue | $78M | $205M | $95M | $165M | $43M | $150M |
|---|
| Olumiant Royalty | $80M | $111M | $221M | $135M | $136M | $145M |
|---|
| OPZELURA | N/A | N/A | $5M | $129M | $508M | $678M |
|---|
| PEMAZYRE Royalty Revenues | N/A | $26M | $109M | $85M | $84M | $87M |
|---|
| Tabrecta Royalty Revenues | N/A | $4M | $10M | $15M | $23M | $27M |
|---|
| ZYNYZ | N/A | N/A | N/A | N/A | $3M | $66M |
|---|
| $4.0B |
| $4.8B |
| UNITED STATES | N/A | N/A | N/A | $3.2B | N/A | N/A |
|---|
| $2.67B |
| +$507.94M |
| +23.53% |
| 2019 | $2.16B | +$276.88M | +14.71% |
| 2018 | $1.88B | +$345.67M | +22.50% |
| 2017 | $1.54B | +$430.50M | +38.93% |
| 2016 | $1.11B | +$351.97M | +46.70% |
